Crucial US Advisory Committee to Decide on Changing Infant Hepatitis B Vaccine Advisory

Following a delay and a particularly heated gathering, a government vaccine expert group was scheduled to decide on Friday on whether to change the enduring advisory that all newborns be immunized against hepatitis B.

Fiery Exchange and a Delayed Ballot

The first day of the conference on Thursday was characterized by intense argument over limiting availability to the hepatitis B vaccine for infants and a decision to postpone the decision by a day to allow panelists additional time to review the wording. The group, which advises the national health agency on vaccination protocols, had previously delayed on two occasions.

“Is there any specific evidence of injury of giving this immunization before 30 days? Or is this theory?” questioned one committee member.

In response, another attendee stated, “There is inadequate data about the prolonged hazard.”

Present Protocol and Possible Consequences

The shot is presently advised for each baby within 24 hours of being born to halt contraction of hepatitis B, which can result in significant hepatic injury. It has been provided to over a billion individuals for more than three decades.

The meeting in Atlanta presented no new evidence of injuries resulting from the vaccine. Authorities state any change to the current hepatitis B vaccine regimen could have significant and far-reaching repercussions for infant and child health in the United States.

Panel Composition and Latest Shifts

The advisory panel can only provide advice to the head of the CDC. The panel's membership has undergone changes this week, with the announcement that the panel's latest chairman would depart for an formal position and be substituted with a cardiac doctor who has been skeptical about other vaccines.

The board includes multiple vaccine skeptics who align with a desire to overhaul – and possibly, in some cases, eliminate – longstanding vaccination recommendations.